Skip to main content
SpringerLink
Log in

Pentafuside

DP 178, T 20

  • Section 2: HIV Fusion Inhibitor
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Johnson MR, Lambert DM, Hopkins S, et al. Pentafuside: an amphipathic helical peptide-based membrane fusion inhibitor directed against HIV-1 GP41 [abstract 252]. 211th American Chemical Society National Meeting; 1996 Mar 24–28; New Orleans, 211

    Google Scholar 

  2. Johnson MR, Lambert DM, Hopkins S, et al. T-20: a peptidebased membrane fusion inhibitor directed against HIV-1 gp41. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 2; Washington, DC, 115

    Google Scholar 

  3. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998 Nov; 4: 1302–7

    Article  PubMed  CAS  Google Scholar 

  4. Trimeris Inc; preliminary phase II clinical trial results of T-20 announced. Daniel J Denoon’s Insider NewsFile [online]. 1999 Feb 16. URL: http://www.newspage.com [Accessed 1999 Mar 12]

    Google Scholar 

  5. Saag M, Alldredge L, Kilby M, et al. A short-term assessment of the safety, kinetics, and antiviral activity of T-29, an inhibitor of gp41 mediated membrane fusion [abstract]. Infectious Disease Society of America (IDSA) 35th Annual Meeting; 1997 Sep 13–16; San Francisco, URL: http://207.78.88.28/-IDSA97/abstract/a774.html [Accessed 1997 Nov 28]

    Google Scholar 

  6. Trimeris to announce preliminary phase II clinical trial results of T-20, a novel HIV drug. BW HealthWire [online]. 1999 Jan 26. URL: http://www.newspage.com [Accessed 1999 Feb 10]

  7. Black PL, Wood O, Broud D, et al. T-20, a novel inhibitor of HIV-1 fusion, blocks recovery of infectious HIV-1 and inhibits viral load in vivo in the HuPBMC-SCID mouse model. 11th International Conference on AIDS; 1996 Jul 7–12; Vancouver, 1: 221

    Google Scholar 

  8. Wild C. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Human Retroviruses 1993 Nov; 9: 1051–3

    Article  CAS  Google Scholar 

  9. Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994 Oct 11; 91: 9770–4

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pentafuside. Drugs R&D 2, 347–349 (1999). https://doi.org/10.2165/00126839-199902050-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902050-00016

Keywords

Search

Navigation